** Shares of some U.S. drugmakers fall premarket after U.S. President Donald Trump reiterated plans for a "major" tariff on all pharmaceutical imports as his "reciprocal" tariffs took effect
** Trump had also threatened the duties on Friday, after his first set of "reciprocal" tariffs announced last week exempted pharma products
** Shares of Gilead Sciences GILD.O down 2.6%, Eli Lilly LLY.N down 1.5%, Biogen BIIB.O down 1.1% and Pfizer PFE.N down 2.8%
** Amgen AMGN.O shares fall 2.3%, Merck MRK.N down 2%, AbbVie ABBV.N down 2.5%
** The U.S. president has said that the tariffs will incentivize drug companies to move their operations to the U.S.
** Brokerage BMO Capital Markets says the tariffs on pharmaceuticals will "likely do little to shift manufacturing back to the US" as the country already has robust biomanufacturing and fill-and-finish onshore
** Up to last close, LLY down 5.9%, MRK down 20.6%, BIIB down 25.4%, AMGN up 7.5% and GILD up 11.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.